Aspirin therapy for cardiovascular disease

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Inflammation Research

Background:

• Aspirin is a well-established antithrombotic medication.
• Its anti-inflammatory actions involve inhibiting cyclooxygenase-2 (COX-2) and nuclear factor-kappa B (NF-kappa B).
• Optimal dosing for preventing cerebral ischemia remains under discussion.

Purpose of the Study:

• To review aspirin's efficacy and limitations in various thrombotic and inflammatory conditions.
• To discuss the role of different aspirin dosages.
• To highlight emerging aspirin derivatives.

Main Methods:

• Review of recent scientific literature on aspirin's mechanisms and clinical applications.
• Analysis of studies on aspirin's effectiveness in thrombosis, restenosis, and stroke prevention.
• Examination of data on combined warfarin-aspirin therapy and novel aspirin derivatives.

Main Results:

• Aspirin effectively inhibits platelet-mediated thrombosis at vascular injury sites.
• It does not consistently prevent restenosis after procedures like coronary angioplasty or carotid endarterectomy.
• It also does not prevent a first stroke.
• Combined warfarin and aspirin therapy reduces systemic emboli in high-risk patients but increases bleeding risk.
• A new aspirin derivative shows potential for stimulating nitric oxide release, inhibiting platelet aggregation, and reducing gastric toxicity.

Conclusions:

• Aspirin is a potent antithrombotic agent with anti-inflammatory properties.
• Its clinical utility is well-defined for thrombosis, but its role in preventing primary stroke and post-procedural restenosis is limited.
• Ongoing research into aspirin derivatives aims to enhance therapeutic benefits while mitigating adverse effects like gastric toxicity.